홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.0
  1. 홈
  2. /반응

Potassium Carbonate → HCID 131729651, 화합물

HRID 1695303
노트
인쇄 미리보기

반응식

HRID 1695303 반응식
[CH3:1]/[CH:2]=[C:3]1/[CH2:4][CH:5]2[N:16]([CH2:17]/1)[C:14](=[O:15])[C:13]1[C:8](=[CH:9][C:10]([OH:20])=[C:11]([O:18][CH3:19])[CH:12]=1)[N:7]=[CH:6]2.[C:21](=[O:24])([O-])[O-].[K+].[K+].[C:27]([O:31][C:32]([NH:34][CH2:35][CH2:36][CH2:37][O:38][C:39]1[CH:44]=[C:43]([CH2:45][O:46]S(C2C=CC(C)=CC=2)(=O)=O)[N:42]=[C:41]([CH2:57]OS(C2C=CC(C)=CC=2)(=O)=O)[CH:40]=1)=[O:33])([CH3:30])([CH3:29])[CH3:28]>CN(C)C=O.[I-].[K+]>[C:27]([O:31][C:32]([NH:34][CH2:35][CH2:36][CH2:37][O:38][C:39]1[CH:40]=[C:41]([CH2:57][O:20][C:10]2[C:11]([O:18][CH3:19])=[CH:12][C:13]3[C:14](=[O:15])[N:16]4[CH2:17][C:3](=[CH:2][CH3:1])[CH2:4][C@H:5]4[CH:6]=[N:7][C:8]=3[CH:9]=2)[N:42]=[C:43]([CH2:45][O:46][C:10]2[C:11]([O:24][CH3:21])=[CH:12][C:13]3[C:14](=[O:15])[N:16]4[CH2:17][C:3](=[CH:2][CH3:1])[CH2:4][C@H:5]4[CH:6]=[N:7][C:8]=3[CH:9]=2)[CH:44]=1)=[O:33])([CH3:28])([CH3:29])[CH3:30]
참가 물질반응 조건실험 절차후처리출처 및 근거반응 노트

참가 물질

6

반응물 3

HCID 11430Potassium CarbonateHCID 5856240PRETOMAYMYCINHCID 71496931HCID 71496931, 화합물

생성물 1

HCID 131729651HCID 131729651, 화합물수율 18.4%

시약·촉매·용매 2

HCID 4875Potassium Iodide용매HCID 6228
Dimethylformamide
용매
2회

반응 조건

온도
30 °C

실험 절차

To a stirred solution of pre-tomaymycin (30 mg) in dimethylformamide (0.5 mL), were added potassium carbonate (45.7 mg), a solution of 4-(3-tert-butoxycarbonylamino-propoxy)-2,6-bis-(tosyloxymethyl)-pyridine (41 mg) in dimethylformamide (0.5 mL) and potassium iodide (18.3 mg). The reaction was stirred for 20 h at 30° C. Solids were filtered off and washed with dimethylformamide (0.2 mL). Water (0.5 mL) was added to the combined dimethylformamide solution and formic acid was added until complete dissolution of the precipitate. The resulting solution was injected for HPLC purification according to method B1. The appropriate fractions were combined and concentrated by centrifugal evaporation over a Jouan Model RC10.10. apparatus to afford 8,8′-[4-(3-tert-butoxycarbonylaminopropyloxy)-2,6-pyridine-diylbis(methylenoxy)]-bis[(S)-2-eth-(E)-ylidene-7-methoxy-1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepin-5-one] (8.3 mg).

후처리

  1. filtrationSolids were filtered off
  2. washwashed with dimethylformamide (0.2 mL)
  3. additionWater (0.5 mL) was added to the combined dimethylformamide solution and formic acid
  4. additionwas added until complete dissolution of the precipitate
  5. customThe resulting solution was injected for HPLC purification
  6. concentrationconcentrated by centrifugal evaporation over a Jouan Model RC10.10

출처 및 근거

ORD 기록
ord-7b69c926b35c453682abf1e131e0ad0c
출처 데이터셋
uspto-grants-2012_04
DOI
10.6084/m9.figshare.5104873.v1
특허 번호
US08163736B2

반응 노트

불러오는 중…

이 페이지에서참가 물질반응 조건실험 절차후처리출처 및 근거반응 노트